Evidence map›Paper›PMID 38009743›Full record

ArticleHistology and histopathology2024

UBE2R2-AS1, as a prognostic marker of gastric cancer, promotes the malignant phenotype of gastric cancer cells.

Jie Xu, Meiqin Xiao, Zhijun Huang, Zhiyao Chen, Jianqing Lin

Abstract read
PubMed Publisher
In one paragraph

Article in Histology and histopathology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 100% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Jie Xu *Department of Gastrointestinal and Esophageal Surgery, the 2nd Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian, PR China.
Meiqin Xiao *Department of Gynecology and Obstetrics, the First Hospital of Quanzhou, Quanzhou, Fujian, PR China.
Zhijun HuangDepartment of Gastrointestinal and Esophageal Surgery, the 2nd Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian, PR China.
Zhiyao ChenDepartment of Gastrointestinal and Esophageal Surgery, the 2nd Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian, PR China.
Jianqing LinDepartment of Oncology Surgery, the 2nd Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian, PR China. Linjianqing6807@163.com.
Fujian Medical University · CNThe 180th Hospital of PLA · CN

Funding

Medical Innovation Foundation of Fujian 2019-CXB-19Natural Science Foundation of Fujian Province 2021J01273Quanzhou High-level Talent Plan 2020C003RQuanzhou High-level Talent Plan 2022C001R
6 · The paper itself

Abstract

BACKGROUND AND

objectivesThis study aimed to unveil the potential of UBE2R2-AS1 dysregulation in gastric cancer. In addition, its biological function was assessed. MATERIALS AND

methodsUBE2R2-AS1 expression was predicted in the ENCORI database. Paired gastric cancer and noncancerous tissues were collected. UBE2R2-AS1 expression was confirmed using RT-qPCR in our patient set. The association of UBE2R2-AS1 with the clinical data of patients was analyzed. Evaluation of the prognostic value of UBE2R2-AS1 was via Kaplan-Meier and Univariate/Multivariate Cox analyses. The effect of UBE2R2-AS1 on the cancer cell malignant phenotype was investigated.

resultsGastric cancer tissues and cells significantly overexpressed UBE2R2-AS1. UBE2R2-AS1 was significantly more abundant in unfavorable clinical pathology, including advanced TNM stage and lymph node metastasis. High expression of UBE2R2-AS1 predicted a poor prognosis with a hazard ratio (HR) of 3.041 and 2.805 after Univariate and Multivariate Cox analysis, respectively. UBE2R2-AS1 can act as a sponge for miR-302b-5p to promote cell proliferation, migration, and invasion of gastric cancer.

conclusionThe expression of UBE2R2-AS1 allowed the prognostic stratification of gastric cancer patients. UBE2R2-AS1 may accelerate the progression of gastric cancer via miR-302b-5p.

Indexed as

Biomarkers, TumorRNA, Long NoncodingStomach NeoplasmsAgedCell Line, TumorCell MovementCell ProliferationFemaleGene Expression Regulation, NeoplasticHumansMaleMicroRNAsMiddle AgedPhenotypePrognosisBiomarkers, TumorMicroRNAsRNA, Long Noncoding

Identifiers

PMID38009743
OpenAlexW4389099387

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.